Latest Breaking News On - கரிபூ உயிர் அறிவியல் இன்க் - Page 1 : comparemela.com
Global CAR-T Cell Therapy Market to 2028: A Potential $15 Billion Industry with Major Focus on Diffuse Large B-Cell Lymphoma (DLBCL) Indication in 2020-2021
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
The global CRISPR market growth is anticipated to progress
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
China Orders Tencent to Give Up Exclusive Music Rights
PropertyGuru to Go Public in $1.8 Billion Deal With Thiel SPAC
Unprecedented Flow of Easy Money Keeps India Stocks on Bull Run
Singapore Stocks Bounce Past Lockdown to Outperform Asian Peers
South Korea Passes Extra Budget With Handouts to Most Households
Sanchez, on Naturgy, Says Spain Welcomes All Foreign Investors
Water Pipe Distributor Core & Main Leads in Friday Debut Gains
Jam City Ends SPAC Deal That Would Have Made $1.2 Billion Firm
Venezuelans Enduring Day-Long Waits to Fill Gasoline Tanks
Day traders take Wall Street by storm again in record dip buying
From Tiger to Temasek, Investors Scarred by China EdTech Assault
Couchbase raises $200 million in upsized IPO that tops price targets - San Francisco Business Times
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
BERKELEY, Calif. (BUSINESS WIRE) Jul 22, 2021
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the pricing of its upsized initial public offering of 19,000,000 shares of common stock at a public offering price of $16.00 per share. All of the shares of common stock are being offered by Caribou. The gross proceeds of the offering, before deducting underwriting discounts and commissions, and other offering expenses payable by Caribou, are expected to be $304.0 million. In addition, Caribou has granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.